Merit Medical(MMSI) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported total revenue of $393.9 million for Q4 2025, an 11% increase year-over-year on a GAAP basis and a 10% increase on a constant currency basis [5][6] - Non-GAAP operating margin increased by 138 basis points year-over-year to 21% [7] - Non-GAAP EPS grew by 12%, exceeding expectations, and free cash flow reached $74 million, a 13% increase year-over-year [8][19] - For the full year 2025, constant currency revenue growth was 11%, with a non-GAAP operating margin of 20.3% and free cash flow exceeding $215 million [9][19] Business Line Data and Key Metrics Changes - Q4 revenue growth was driven by a 9% increase in the cardiovascular segment and a 15% increase in the endoscopy segment [10] - Cardiac Intervention product sales increased by 21%, while Peripheral Intervention products saw a 13% increase [11][12] - Sales of OEM products decreased by 15%, attributed to inventory destocking and macroeconomic factors [14][15] Market Data and Key Metrics Changes - U.S. sales increased by 12% year-over-year, while international sales grew by 6% [16] - Organic constant currency growth in the U.S. was 8%, and 4% internationally [16] Company Strategy and Development Direction - The company aims for solid constant currency growth and non-GAAP operating margin expansion in 2026, with a focus on executing its Continued Growth Initiatives program [9][10] - The divestiture of the DualCap product line is expected to enhance manufacturing capacity and free up resources for higher-margin products [24][40] - The company is prioritizing R&D efforts and exploring M&A opportunities to drive growth [39][59] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the global macro environment but expressed optimism about the company's performance and future growth [9][10] - The CEO emphasized the importance of internal feedback and engagement with stakeholders to inform strategic decisions [30][33] Other Important Information - The company expects free cash flow of at least $200 million in 2026, with planned capital expenditures of approximately $90 million [27][55] - The anticipated impact of tariffs on non-GAAP EPS for 2026 is approximately $15 million [25][26] Q&A Session Summary Question: What are the additional gross margin drivers for the company? - Management highlighted the focus on product mix, pricing discipline, and cost management as key drivers for gross margin improvement [43][46] Question: How is the WRAPSODY product performing in the market? - Management acknowledged that initial revenue expectations for WRAPSODY were not met but expressed confidence in achieving the $7 million revenue target for 2026 [48][50] Question: What are the strategic areas for M&A? - The company is looking at both foundational and therapeutic products for potential acquisitions, aiming to fill gaps in their product offerings [58][59] Question: What is the impact of the DualCap divestiture on margins and EPS? - The divestiture is expected to have a minimal EPS impact but will create a 140 basis point headwind to revenue growth [81][84]